Alps Advisors Inc Arcus Biosciences, Inc. Transaction History

Alps Advisors Inc

  • $14.8 Billion
  • Q3 2024

A detailed history of Alps Advisors Inc transactions in Arcus Biosciences, Inc. stock. As of the latest transaction made, Alps Advisors Inc holds 68,362 shares of RCUS stock, worth $1 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
68,362
Previous 70,948 3.64%
Holding current value
$1 Million
Previous $1.08 Million 3.24%
% of portfolio
0.01%
Previous 0.01%

Shares

16 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024
SELL
$13.69 - $18.01 $35,402 - $46,573
-2,586 Reduced 3.64%
68,362 $1.05 Million
Q2 2024

Aug 13, 2024
BUY
$14.59 - $18.48 $100,058 - $126,735
6,858 Added 10.7%
70,948 $1.08 Million
Q1 2024

May 14, 2024
BUY
$14.83 - $20.18 $172,309 - $234,471
11,619 Added 22.14%
64,090 $1.21 Million
Q4 2023

Feb 14, 2024
SELL
$13.43 - $19.63 $33,306 - $48,682
-2,480 Reduced 4.51%
52,471 $1 Million
Q3 2023

Nov 14, 2023
BUY
$17.62 - $23.54 $21,390 - $28,577
1,214 Added 2.26%
54,951 $986,000
Q2 2023

Aug 14, 2023
BUY
$16.97 - $22.03 $95,659 - $124,183
5,637 Added 11.72%
53,737 $1.09 Million
Q1 2023

May 10, 2023
SELL
$15.96 - $23.15 $10,773 - $15,626
-675 Reduced 1.38%
48,100 $877,000
Q4 2022

Feb 14, 2023
BUY
$19.7 - $35.71 $185,180 - $335,674
9,400 Added 23.87%
48,775 $1.01 Million
Q3 2022

Nov 14, 2022
SELL
$23.23 - $30.07 $73,732 - $95,442
-3,174 Reduced 7.46%
39,375 $1.03 Million
Q2 2022

Aug 11, 2022
SELL
$17.23 - $37.73 $525,359 - $1.15 Million
-30,491 Reduced 41.75%
42,549 $1.08 Million
Q1 2022

May 16, 2022
SELL
$28.92 - $41.83 $238,734 - $345,306
-8,255 Reduced 10.15%
73,040 $2.31 Million
Q4 2021

Feb 09, 2022
SELL
$31.38 - $48.47 $194,807 - $300,901
-6,208 Reduced 7.09%
81,295 $3.29 Million
Q3 2021

Nov 15, 2021
SELL
$26.93 - $37.68 $161,660 - $226,193
-6,003 Reduced 6.42%
87,503 $3.05 Million
Q2 2021

Aug 11, 2021
SELL
$22.75 - $35.77 $544,748 - $856,512
-23,945 Reduced 20.39%
93,506 $2.57 Million
Q1 2021

May 07, 2021
BUY
$26.16 - $41.39 $3,479 - $5,504
133 Added 0.11%
117,451 $3.3 Million
Q4 2020

Feb 03, 2021
BUY
$17.0 - $32.36 $1.99 Million - $3.8 Million
117,318 New
117,318 $3.05 Million

Others Institutions Holding RCUS

# of Institutions
201
Shares Held
51.7M
Call Options Held
236K
Put Options Held
141K
View Full List

About Arcus Biosciences, Inc.

RCUS Quotes by TradingView
  • Ticker RCUS
  • Exchange NYSE
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 72,160,000
  • Market Cap $1.06B
  • Description
  • Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. Its product pipeline includes, Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 clinical trial; and Zimberelimab, an anti-PD-1 antibody that is in Phase 1b clinical trial for ...
More about RCUS
Track This Portfolio

Track Alps Advisors Inc Portfolio

Follow Alps Advisors Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Alps Advisors Inc, based on Form 13F filings with the SEC.

News

Stay updated on Alps Advisors Inc with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email